Hutch News

Hutch News

Stories tagged 'CAR t-cell'

Jump-starting innovative projects exploring pathogen-associated cancers

Pathogen-Associated Malignancies Integrated Research Center awards first round of pilot funding supporting researchers studying H. pylori, EBV and the microbiome

March 16, 2018 | By Sabrina Richards

Announcing the inaugural recipients of the PAM IRC Innovation Awards for innovative projects exploring pathogens associated with cancer.

View story >


How new drugs become available to more patients

Filling in the unknowns on the balance between risk and benefit

Feb. 9, 2018 | by Susan Keown / Fred Hutch News Service

Often, new drugs are only approved to treat patients with advanced disease. But that can change as evidence accrues on the drugs’ risks and benefits.

View story >


10 highlights of Fred Hutch science in 2017

A look back at notable discoveries in cancer immunotherapy, HIV prevention and more

Dec. 28, 2017 | by Sabin Russell and Susan Keown / Fred Hutch News Service

It's been a year of breakthroughs at Fred Hutch. Here are 10 of our favorites.

View story >


New insights into CAR T-cell therapy's potential side effects

Detailed study of cytokine release syndrome and neurologic toxicities could help make emerging cancer immunotherapies safer

Dec. 11, 2017 | By Fred Hutch staff

Detailed studies of two potential side effects of an emerging cancer immunotherapy could eventually help make this strategy, CAR T-cell therapy, safer for patients. The studies examined cytokine release syndrome and neurologic toxicities.

View story >


First systematic study of infections after CAR T-cell therapy

“Benchmark” research could help reduce complications of emerging immunotherapy

Nov. 6, 2017 | by Susan Keown / Fred Hutch News Service

The first detailed study of infections after CAR T-cell therapy could help researchers improve the safety of this emerging type of genetically engineered cell therapy for cancer.

View story >


Mourning the loss of Dr. Oliver 'Ollie' Press

Lymphoma physician-scientist, leader and mentor made lifesaving contributions to the development of targeted cancer therapies

Oct. 2, 2017 | by Susan Keown / Fred Hutch News Service

Dr. Oliver Press died of complications from glioma, a brain cancer. Press was a physician-scientist who made foundational contributions to the development of targeted therapies for blood cancers.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.